drugset / Trial / NCT01499004

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

NCT01499004

Phase 1 Completed 30 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study will explore the drug behavior and safety following a single dose of three different 22 milligram tofacitinib (CP-690,550) modified-release formulations in 30 healthy volunteers. These formulations will be compared to 10 milligram tofacitinib (CP-690-550) in an immediate-release formulation.

Timeline

Start
2011-11
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tofacitinib Small molecule 10 mg
Subject Tofacitinib Small molecule 22 mg

Indications

No indication recorded.